{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:39:15Z","timestamp":1793975955494,"version":"4.8.0"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape of hematologic malignancies, delivering durable remissions in diseases previously associated with poor outcomes. However, translating this success to solid tumors has proven challenging due to antigen heterogeneity, limited tumor infiltration, immunosuppressive tumor microenvironments, and progressive T-cell exhaustion. In response, next-generation CAR T-cell platforms have emerged that integrate advances in receptor architecture, intracellular signaling, and programmable control systems to enhance specificity, persistence, and safety. This review comprehensively examines recent innovations in CAR T-cell engineering, including optimization of extracellular binding domains, hinge and transmembrane modifications, fine-tuning of intracellular signaling motifs, and the incorporation of alternative protein scaffolds. We discuss logic-gated strategies such as synNotch receptors, inducible ON-switch CARs, inhibitory CARs, and modular adaptor systems that enable context-dependent activation and reduce off-tumor toxicity. In parallel, we explore approaches aimed at overcoming T-cell dysfunction through intrinsic checkpoint rewiring, cytokine armoring, and epigenetic reprogramming to sustain antitumor activity in hostile microenvironments. The development of allogeneic and off-the-shelf CAR T-cell products derived from healthy donors, induced pluripotent stem cells, natural killer cells, \u03b3\u03b4 T cells, and macrophages is also reviewed, highlighting strategies to mitigate graft-versus-host disease and host immune rejection while enabling scalable manufacturing. Finally, we address current translational bottlenecks related to immunogenicity, regulatory complexity, and production logistics, and outline future directions for integrating Boolean logic circuits, safety switches, and automated GMP-compliant processes. Collectively, these advances position next-generation CAR T-cell therapies as programmable and adaptable immunotherapeutic platforms with the potential to extend durable clinical benefit beyond hematologic cancers into solid tumors.<\/jats:p>","DOI":"10.3389\/fonc.2025.1698442","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:15:13Z","timestamp":1767935713000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance"],"prefix":"10.3389","volume":"15","author":[{"given":"Juan Esteban","family":"Garcia-Robledo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Cabrera-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Michael","family":"Brandauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Rengifo-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Toro-Pedroza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Sebasti\u00e1n","family":"Victoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lady J.","family":"Rios-Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Loukanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s Felipe","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Camilo","family":"Baena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1200914","article-title":"ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype","volume":"13","author":"Moreno-Cortes","year":"2023","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.56875\/2589-0646.1035","article-title":"Next-Generation Chimeric Antigen Receptor T-cells","volume":"15","author":"Yi","year":"2022","journal-title":"Hematol\/Oncol Stem Cell Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"100264","DOI":"10.1016\/j.jtauto.2024.100264","article-title":"Cellular therapies in rheumatic and musculoskeletal diseases","volume":"10","author":"Franco-Fuquen","year":"2025","journal-title":"J Transl Autoimmun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/biomedicines9010059","article-title":"Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections","volume":"9","author":"Zmievskaya","year":"2021","journal-title":"Biomedicines"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T Therapies in Solid Tumors: Opportunities and Challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"216871","DOI":"10.1016\/j.canlet.2024.216871","article-title":"The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors","volume":"591","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.004","article-title":"CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials","volume":"33","author":"Begley","year":"2025","journal-title":"Mol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T Cells for Next-Generation Cancer Therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-191254","article-title":"Novel Peptide-Based Plectin-1 CAR T-Cells Target Specifically Pancreatic Cancer Cells","volume":"142","author":"Garcia-Robledo","year":"2023","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/s41467-023-37616-4","article-title":"The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"387\u2013405","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2022","volume":"20","author":"Thompson","year":"2022","journal-title":"NCCN Clin Pract Guidel Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01658-z","article-title":"Harnessing CD3 diversity to optimize CAR T cells","volume":"24","author":"Velasco C\u00e1rdenas","year":"2023","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"12201","DOI":"10.3390\/ijms252212201","article-title":"Significant Advancements and Evolutions in Chimeric Antigen Receptor Design","volume":"25","author":"Gaimari","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cell.2017.08.018","article-title":"Mitochondrial Priming by CD28","volume":"171","author":"Klein Geltink","year":"2017","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: From Mechanism to Therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2559","article-title":"Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor\u2013engineered T Cells","volume":"25","author":"Drent","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171068","article-title":"4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses","volume":"215","author":"Menk","year":"2018","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxae007","article-title":"Reprogramming T-cell metabolism to enhance adoptive cell therapies","volume":"36","author":"Kates","year":"2024","journal-title":"Int Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00304","article-title":"ICOS Co-Stimulation: Friend or Foe","volume":"7","author":"Wikenheiser","year":"2016","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203485","article-title":"Phosphatidylinositol 3-Kinase\u2013Independent Signaling Pathways Contribute to ICOS-Mediated T Cell Costimulation in Acute Graft-Versus-Host Disease in Mice","volume":"191","author":"Li","year":"2013","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","article-title":"Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells","volume":"15","author":"Tan","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"23024","DOI":"10.1038\/s41598-023-48528-0","article-title":"Solving the mystery of the FMC63-CD19 affinity","volume":"13","author":"Seigner","year":"2023","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The Therapeutic Potential of Nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1479","article-title":"Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors","volume":"25","author":"Balakrishnan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00048-8","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","article-title":"Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy","volume":"55","author":"Pl\u00fcckthun","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.021","article-title":"Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells","volume":"28","author":"Siegler","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-020-00692-0","article-title":"Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4+ T cells to reduce the latent HIV+ cell reservoir","volume":"209","author":"Patasic","year":"2020","journal-title":"Med Microbiol Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.02.024","article-title":"Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments","volume":"26","author":"Nix","year":"2024","journal-title":"Cytotherapy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.009","article-title":"Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering","volume":"25","author":"Han","year":"2017","journal-title":"Mol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198499","article-title":"Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and\/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial","volume":"144","author":"Freeman","year":"2024","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6527","article-title":"Designed protein logic to target cells with precise combinations of surface antigens","volume":"369","author":"Lajoie","year":"2020","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.3390\/cancers14133230","article-title":"Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood-2019-123277","article-title":"Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma","volume":"134","author":"Sakemura","year":"2019","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaneurol.2024.3818","article-title":"Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review","volume":"82","author":"Ismail","year":"2025","journal-title":"JAMA Neurol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1664403","article-title":"Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together","volume":"16","author":"Bernard","year":"2025","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.008","article-title":"Refining chimeric antigen receptors via barcoded protein domain combination pooled screening","volume":"31","author":"Rios","year":"2023","journal-title":"Mol Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.3390\/ijms23074056","article-title":"The Effects of Chimeric Antigen Receptor (CAR) Hinge Domain Post-Translational Modifications on CAR-T Cell Activity","volume":"23","author":"Hirobe","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03195-4","article-title":"Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor","volume":"71","author":"Wang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864868","article-title":"Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation","volume":"13","author":"McComb","year":"2022","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.3390\/cells11213386","article-title":"Modification of Hinge\/Transmembrane and Signal Transduction Domains Improves the Expression and Signaling Threshold of GXMR-CAR Specific to Cryptococcus spp","volume":"11","author":"Dos Santos","year":"2022","journal-title":"Cells"},{"key":"B50","first-page":"1398","article-title":"CD3 zeta ITAM diversity determines chimeric antigen receptor force and function","volume":"212","author":"Echelibe","year":"2024","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700069","article-title":"Cutting Edge: CD3 ITAM Diversity Is Required for Optimal TCR Signaling and Thymocyte Development","volume":"199","author":"Bettini","year":"2017","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e005691","DOI":"10.1136\/jitc-2022-005691","article-title":"Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models","volume":"11","author":"Schoutrop","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1509980","article-title":"The impact of CD3\u03b6 ITAM multiplicity and sequence on CAR T-cell survival and function","volume":"15","author":"Majumdar","year":"2025","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the Antigen Density Requirement for CAR T-cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/pr10010016","article-title":"A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9","volume":"10","author":"Saber","year":"2022","journal-title":"Processes"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK Cells: From Natural Basis to Design for Kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1182\/blood-2021-154176","article-title":"Preclinical NK Cell Platform for CAR Directed Therapies: Functional and Phenotypic Comparison Using a Rechallenge Cytotoxicity Assay","volume":"138","author":"Forero","year":"2021","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.05.008","article-title":"Concept CARs are picking up speed","volume":"33","author":"Mansilla-Soto","year":"2025","journal-title":"Mol Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13255","article-title":"Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer","volume":"320","author":"Li","year":"2023","journal-title":"Immunol Rev"},{"key":"B62","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13046-025-03351-5","article-title":"A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells","volume":"44","author":"Yi","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of Engineering Immune Cells to Treat Cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"9917","DOI":"10.1038\/s41467-024-53996-7","article-title":"Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters","volume":"15","author":"Park","year":"2024","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e010028","DOI":"10.1136\/jitc-2024-010028","article-title":"ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis","volume":"12","author":"Cao","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/2326-6066.CIR-24-0051","article-title":"CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial","volume":"13","author":"Xu","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T\u2009cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B\u2009cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312374120","article-title":"Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e004185","DOI":"10.1136\/jitc-2021-004185","article-title":"To go or not to go? Biological logic gating engineered T cells","volume":"10","author":"Abbott","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1158\/1538-7445.AM2020-2661","article-title":"Abstract 2661: AUTO6NG overcomes immune suppressive mechanisms in the TME and demonstrate preclinical anti-tumor activity in GD2-expressing solid tumors","volume":"80","author":"Neves","year":"2020","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.12.009","article-title":"Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches","volume":"12","author":"Duong","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/bioengineering12010060","article-title":"iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment","volume":"12","author":"Zong","year":"2025","journal-title":"Bioengineering"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.601","article-title":"Enhancing iPSC-CMs maturation using a Matrigel-coated micropatterned PDMS substrate","volume":"2","author":"Jimenez-Vazquez","year":"2022","journal-title":"Curr Protoc"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1038\/srep03594","article-title":"A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells","volume":"4","author":"Nakagawa","year":"2014","journal-title":"Sci Rep"},{"key":"B87","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.stem.2024.10.004","article-title":"Maturation and persistence of CAR T cells derived from human pluripotent stem cells via chemical inhibition of G9a\/GLP","volume":"32","author":"Jing","year":"2025","journal-title":"Cell Stem Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","article-title":"3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Stem Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B90","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12896-020-00665-4","article-title":"CRISPR\/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells","volume":"21","author":"Kamali","year":"2021","journal-title":"BMC Biotechnol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","article-title":"Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer","volume":"14","author":"Lyu","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3390\/v15071510","article-title":"Virus-Specific T-Cell Therapy for Viral Infections of the Central Nervous System: A Review","volume":"15","author":"Lambert","year":"2023","journal-title":"Viruses"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T Cells: More than Ease of Access","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T Cells that Express a PD-1\/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"101085","DOI":"10.1016\/j.tranon.2021.101085","article-title":"A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma","volume":"14","author":"Liu","year":"2021","journal-title":"Transl Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"B99","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40164-023-00450-x","article-title":"CRISPR\/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro","volume":"12","author":"Liu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13058-022-01531-1","article-title":"Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC","volume":"24","author":"Harrasser","year":"2022","journal-title":"Breast Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2543","article-title":"Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors","volume":"42","author":"Nakajima","year":"2024","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0400","article-title":"Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19","volume":"21","author":"Tokunaga","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02339-4","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","volume":"43","author":"Rakhshandehroo","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1038\/s41467-023-40115-1","article-title":"Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting","volume":"14","author":"Lee","year":"2023","journal-title":"Nat Commun"},{"key":"B109","doi-asserted-by":"publisher","first-page":"156973","DOI":"10.1016\/j.cyto.2025.156973","article-title":"Interleukin-enhanced CAR-engineered immune cells in tumor immunotherapy: current insights and future perspectives","volume":"192","author":"Wang","year":"2025","journal-title":"Cytokine"},{"key":"B110","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2025.09.004","article-title":"Designing immunity with cytokines: A logic-based framework for programmable CAR therapies","volume":"86","author":"Upadhyay","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"B112","doi-asserted-by":"publisher","first-page":"113898","DOI":"10.1016\/j.celrep.2024.113898","article-title":"NR4a1\/2 deletion promotes accumulation of TCF1+ stem-like precursors of exhausted CD8+ T cells in the tumor microenvironment","volume":"43","author":"Srirat","year":"2024","journal-title":"Cell Rep"},{"key":"B113","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci Transl Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"10365","DOI":"10.3390\/ijms251910365","article-title":"Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility","volume":"25","author":"Giorgioni","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B116","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00281-024-01019-4","article-title":"Advances in manufacturing chimeric antigen receptor immune cell therapies","volume":"46","author":"Ramamurthy","year":"2024","journal-title":"Semin Immunopathol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/intimm\/dxad033","article-title":"Cytokine signaling in chimeric antigen receptor T-cell therapy","volume":"36","author":"Kagoya","year":"2024","journal-title":"Int Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1090959","article-title":"CAR T cell therapy becomes CHIC: \u201ccytokine help intensified CAR\u201d T cells","volume":"13","author":"Thomas","year":"2023","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1872","article-title":"Cooperative Armoring of CAR and TCR T Cells by T Cell\u2013Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e150807","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0734","article-title":"Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments","volume":"8","author":"Xie","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","article-title":"Nanobody-based CAR-T cells for cancer immunotherapy","volume":"10","author":"Safarzadeh Kozani","year":"2022","journal-title":"biomark Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0640","article-title":"Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors","volume":"11","author":"Righi","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s44272-025-00050-2","article-title":"Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future prospects","volume":"4","author":"Liao","year":"2025","journal-title":"Clin Cancer Bull"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1615212","article-title":"Tracing the development of CAR-T cell design: from concept to next-generation platforms","volume":"16","author":"Alsaieedi","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1698442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:15:15Z","timestamp":1767935715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1698442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":125,"alternative-id":["10.3389\/fonc.2025.1698442"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1698442","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1698442"}}